Scotiabank raised the firm’s price target on BridgeBio (BBIO) to $57 from $55 and keeps an Outperform rating on the shares. The firm continues to be impressed by the company’s early commercial momentum and raises it price target on the stock to reflect updated Attruby sales expectations, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: